ARSACS (Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay) encodes sacsin, a large protein involved in cytoskeletal organization, mitochondrial function, and neuronal protection against oxidative stress. First identified in 2000 as the cause of ARSACS, this gene has since been found to play critical roles in maintaining neuronal integrity. The disease is characterized by early-onset spastic ataxia, peripheral neuropathy, and retinal striation, making it an important model for understanding hereditary ataxias and potentially other neurodegenerative conditions[1].
| Property | Value |
|---|---|
| Gene Symbol | ARSACS |
| Full Name | Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay |
| Chromosomal Location | 13q12.12 |
| NCBI Gene ID | 51399 |
| OMIM | 270550 |
| Ensembl ID | ENSG00000040608 |
| UniProt | Q9BSJ2 |
| Protein Name | Sacsin (SACS) |
| Protein Size | ~520 kDa (largest known neuronal protein) |
Sacsin is one of the largest proteins in the human body, with multiple functional domains:
| Domain | Position | Function |
|---|---|---|
| N-terminal UBL domain | 1-100 aa | Ubiquitin-like, involved in proteasomal targeting |
| Sacsin repeat region | Multiple repeats | Protein-protein interactions |
| HepA-binding domain | Central | Chaperone-like activity |
| C-terminal J-domain | ~4500 aa | Hsp40 co-chaperone function |
The sacsin repeat region contains multiple tandem repeats that are unique to this protein and mediate interactions with various cellular components. The J-domain at the C-terminus indicates involvement in the Hsp40/Hsp70 chaperone system, suggesting a role in protein quality control[2].
Cytoskeletal Organization:
Mitochondrial Function:
Protein Quality Control:
Oxidative Stress Protection:
Clinical Features:
The classic ARSACS phenotype includes:
Disease Progression:
Mechanisms:
Alzheimer's Disease:
Parkinson's Disease:
Other Ataxias:
Clinical Evaluation:
Genetic Testing:
Variant Types:
The specific variant type correlates with disease severity:
| Variant Type | Severity | Notes |
|---|---|---|
| Two null alleles | Severe | Earlier onset, faster progression |
| Compound heterozygous | Variable | Depends on residual function |
| Missense/missense | Mild | Later onset, slower progression[8] |
Current Treatment:
Emerging Therapies:
Sacsin is expressed throughout the nervous system:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Cerebellar Purkinje cells | Very high | Most affected in ataxia |
| Motor neurons | High | Spinal cord involvement |
| Sensory neurons | High | Peripheral neuropathy |
| Retinal neurons | High | Retinal striation |
Sacsin knockout mice:
Zebrafish models:
Sacsin
├── Cytoskeletal system
│ ├── Intermediate filaments
│ ├── Actin cytoskeleton
│ └── Microtubules
├── Mitochondrial dynamics
│ ├── Fusion (Mfn1/2, OPA1)
│ └── Fission (Drp1)
├── Protein quality control
│ ├── Hsp70/Hsp40 system
│ └── Proteasome
└── Antioxidant defense
├── Glutathione metabolism
└── ROS scavenging
Over 150 pathogenic variants have been identified:
| Approach | Status | Notes |
|---|---|---|
| Chaperone therapy | Preclinical | Small molecules to stabilize protein |
| Antioxidants | Research | Reduce oxidative stress |
| Neuroprotective agents | Preclinical | Support neuron survival |
| Mitochondrial modulators | Research | Improve mitochondrial function |
Bouhlal Y, et al. ARSACS: from gene identification to therapeutic approaches. J Neurol Sci. 2019. ↩︎
Thibault M, et al. Sacsin's domains and their functions in protein quality control. J Cell Sci. 2019. ↩︎
Ridone MG, et al. Sacsin and the cytoskeleton: role in neuronal integrity. J Neurosci. 2021. ↩︎
Gerardo M, et al. Sacsin function in mitochondrial dynamics and neurodegeneration. Cell Mol Neurobiol. 2020. ↩︎
Martin A, et al. Sacsin's role in oxidative stress protection in neurons. Free Radic Biol Med. 2020. ↩︎
Tremblay C, et al. Natural history of ARSACS: a longitudinal study. Neurology. 2022. ↩︎
Parrillo L, et al. Molecular genetics of ARSACS: over 150 pathogenic variants. Hum Mutat. 2020. ↩︎
Bauer P, et al. Genotype-phenotype correlation in ARSACS. Brain. 2019. ↩︎
Lopez MJ, et al. Gene therapy approaches for ARSACS. Mol Ther Methods Clin Dev. 2021. ↩︎
Mercier J, et al. Sacsin knockout mice recapitulate human ARSACS phenotype. Hum Mol Genet. 2019. ↩︎
Chen L, et al. Therapeutic strategies for ARSACS: current progress. Orphanet J Rare Dis. 2021. ↩︎